TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26818636

Group type: EXPERIMENTAL
Intervention: Non-invasive programmed stimulation (NIPS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 150
Study: 24500537

Group type: EXPERIMENTAL
Intervention: Gait retraining (supervised exercises for neuromuscular control and flexibility, three sessions per week; biofeedback, one session per week)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (usual military training regimen without gait retraining)
Number of subjects: 166
Study: 22948452

Group type: EXPERIMENTAL
Intervention: Small intestine submucosa graft
Number of subjects: 56

Group type: COMPARATOR
Intervention: Traditional colporrhaphy
Number of subjects: 56
Study: 21056804

Group type: EXPERIMENTAL
Intervention: FIO(2) = 0.8 (Group G80)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FIO(2) = 0.5 (Group G50)
Number of subjects: 120

Group type: COMPARATOR
Intervention: FIO(2) = 0.3 (Group G30)
Number of subjects: 120
Study: 17693652

Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha2b (P-IFN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interferon-alpha2b (IFN)
Number of subjects: 60
Study: 15767215

Group type: EXPERIMENTAL
Intervention: Long-term stavudine therapy (40 mg single dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single-dose stavudine treatment (40 mg)
Number of subjects: 36
Study: 12224599

Group type: EXPERIMENTAL
Intervention: Daily combination of 60 mg soy isoflavones, 100 mg dong quai, and 50 mg black cohosh for 24 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment for 24 weeks
Number of subjects: 49
Study: 10223772

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ebrotidine
Number of subjects: 8
Study: 8714852

Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (Nicardipine, Verapamil, Diltiazem) administered by iontophoresis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (Nicardipine, Verapamil, Diltiazem) administered by iontophoresis in combination with lidocaine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lidocaine administered alone
Number of subjects: 3
Study: 31079232

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 22
Study: 30665306

Group type: EXPERIMENTAL
Intervention: Constant force-induced unfolding of ubiquitin protein at about 400 pN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pearson correlation coefficient analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidimensional transition-state theory
Number of subjects: 0
Study: 27829181

Group type: EXPERIMENTAL
Intervention: Thoracic epidural block (TEB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 60
Study: 25293650

Group type: EXPERIMENTAL
Intervention: Psychotherapy and pharmacotherapy sessions
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Race as a predictor of response, remission, or relapse
Number of subjects: 403
Study: 23441100

Group type: EXPERIMENTAL
Intervention: Freckling score
Number of subjects: 3123

Group type: EXPERIMENTAL
Intervention: Tanning score
Number of subjects: 3123
Study: 21442803

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at Dingchuan (EX-B 1) with frequency of 4 Hz and wave width of 200 ms
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation without current output at Dingchuan (EX-B 1)
Number of subjects: 40
Study: 19047293

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily for 28 days in each 4-week cycle
Number of subjects: 23
Study: 16944408

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg/bd)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15099314

Group type: EXPERIMENTAL
Intervention: Polidocanol (Aethoxysklerol)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 25
Study: 11738097

Group type: EXPERIMENTAL
Intervention: one 250 microg bolus + 250 microg/h infusion
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: three 250 microg boluses + 250 microg/h infusion
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: three 250 microg boluses + 500 microg/h infusion
Number of subjects: 174
Study: 9228962

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months
Number of subjects: 462

Group type: COMPARATOR
Intervention: No vitamin A supplementation with one dose of measles vaccine at age 9 months
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with two doses of measles vaccine at ages 6 and 9 months
Number of subjects: 462

Group type: COMPARATOR
Intervention: No vitamin A supplementation with two doses of measles vaccine at ages 6 and 9 months
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months (boys)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU) with one dose of measles vaccine at age 9 months (girls)
Number of subjects: 462
Study: 7965439

Group type: EXPERIMENTAL
Intervention: 3-week regimen of benzathine penicillin G (1.2 million units every 3 weeks)
Number of subjects: 249

Group type: COMPARATOR
Intervention: 4-week regimen of benzathine penicillin G (1.2 million units every 4 weeks)
Number of subjects: 249
Study: 3656045

Group type: EXPERIMENTAL
Intervention: O'Neil suction cups
Number of subjects: 410

Group type: COMPARATOR
Intervention: Malmström suction cups
Number of subjects: 410
Study: 29635438

Group type: EXPERIMENTAL
Intervention: Cetuximab (n=149)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (n=151)
Number of subjects: 300
Study: 26218586

Group type: EXPERIMENTAL
Intervention: Biphasic immediate‐release (IR)/extended‐release (ER) oxycodone (OC)/acetaminophen (APAP) 7.5/325 mg tablets, total dose 15/650 mg every 12 hours for 4.5 days
Number of subjects: 96
Study: 24637537

Group type: EXPERIMENTAL
Intervention: Abiraterone (1000 mg q.d.) plus low-dose prednisone (5 mg b.i.d.)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 118
Study: 22240264

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) mobilized PBMNCs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 21218679

Group type: EXPERIMENTAL
Intervention: Feeding with oral support
Number of subjects: 20

Group type: COMPARATOR
Intervention: Feeding without oral support
Number of subjects: 20
Study: 18673000

Group type: EXPERIMENTAL
Intervention: Bioabsorbable barrier
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-resorbable barrier
Number of subjects: 12
Study: 16179768

Group type: EXPERIMENTAL
Intervention: Foam-padded gloves
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bare hands
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Air-bladder gloves
Number of subjects: 11
Study: 14708875

Group type: EXPERIMENTAL
Intervention: Pulsatile electromagnetic field treatment (applied for 5 days, two times daily for 30 minutes, magnetic induction: 3 mT, frequency: 4 Hz)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (pharmacological treatment only)
Number of subjects: 42
Study: 10533300

Group type: EXPERIMENTAL
Intervention: Topical latanoprost 50 micrograms/ml
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8692625

Group type: EXPERIMENTAL
Intervention: pH-assisted placement technique
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard placement technique
Number of subjects: 68
Study: 1860093

Group type: EXPERIMENTAL
Intervention: Quinapril (2.5, 5, 10 or 20 mg bid for four weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (four weeks)
Number of subjects: 25
Study: 7106162

Group type: EXPERIMENTAL
Intervention: Methenamine mandelate granules 4 g/day alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Methenamine mandelate granules 4 g/day with ascorbic acid 4 g/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Methenamine mandelate granules 4 g/day with ascorbic acid 4 g/day plus cranberry cocktail 1/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 27
Study: 30794302

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 4 mg, orally twice daily (total daily dose 8 mg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 29389742

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4071

Group type: COMPARATOR
Intervention: Control (discontinue all antihypertensive medications)
Number of subjects: 4071
Study: 26426999

Group type: EXPERIMENTAL
Intervention: Multimodal endoscope with a fluorescently labeled peptide
Number of subjects: 50
Study: 25267661

Group type: EXPERIMENTAL
Intervention: Primaquine (30 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (120/960 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Primaquine combined with dihydroartemisinin-piperaquine
Number of subjects: 16
Study: 22464768

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 50
Study: 20719298

Group type: EXPERIMENTAL
Intervention: Bag-in-the-lens IOL
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control IOL (Alcon AcrySof SA60AT)
Number of subjects: 52
Study: 17606664

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16159655

Group type: EXPERIMENTAL
Intervention: Pre‐incision infiltration of 1.5 ml local anesthetic mixture with general anesthesia (n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pre‐incision infiltration of 1.5 ml of 0.9% normal saline with general anesthesia (placebo, n=30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: General anesthesia only (n=30)
Number of subjects: 90
Study: 12220482

Group type: EXPERIMENTAL
Intervention: Surgery in patients with active IBD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 30
Study: 10355910

Group type: EXPERIMENTAL
Intervention: Phenobarbital and vitamin K
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 7492158

Group type: EXPERIMENTAL
Intervention: Follow on formula milk containing 1.2 mg of iron per 100 ml
Number of subjects: 92

Group type: COMPARATOR
Intervention: Follow on formula milk with no added iron
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups (with and without added iron)
Number of subjects: 92
Study: 2056908

Group type: EXPERIMENTAL
Intervention: Endurance training (75-85% VO2max for 35-45 min three times per week for the last 2 months)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Resistance training (one set of 8-12 repetitions on ten Nautilus machines three times per week)
Number of subjects: 49
Study: 7036276

Group type: EXPERIMENTAL
Intervention: i.v. cyclophosphamide (30 mg/kg) over a 6-day period
Number of subjects: 559

Group type: COMPARATOR
Intervention: Control group (randomized)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 559
Study: 30084414

Group type: EXPERIMENTAL
Intervention: Lamivudine + Tenofovir + EFV (TDF)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lamivudine + Adefovir + Zidovudine + EFV (ADV)
Number of subjects: 78
Study: 28480270

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 26215172

Group type: EXPERIMENTAL
Intervention: Repeated-sprint (RS) training (EXP, 3 times week(-1), 18 maximal all-out 15-m sprints interspersed with 17 s of passive recovery)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CON, n=9)
Number of subjects: 18
Study: 23898691

Group type: EXPERIMENTAL
Intervention: Elastic tubes (ETs) attached to resistance training machines during knee extension exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (without ETs)
Number of subjects: 22
Study: 20058183

Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention
Number of subjects: 362
Study: 17531459

Group type: EXPERIMENTAL
Intervention: CP-CLA (400 mug chromium, 1.8 g CLA in 2.4 g tonalin oil, n=19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (<0.1 microg Cr, 2.4 g canola oil, n=16)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CP-CLA
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CP-CLA and Placebo
Number of subjects: 35
Study: 16600640

Group type: EXPERIMENTAL
Intervention: CCK‐4
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anticipatory Anxiety Challenge
Number of subjects: 12
Study: 14649167

Group type: EXPERIMENTAL
Intervention: Listening to music during a 10-minute walk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Walking without music for 10 minutes
Number of subjects: 30
Study: 11775548

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B alone or combination with flucytosine therapy (Group I)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole alone or combination with flucytosine (Group II)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intrathecal amphotericin B plus intravenous amphotericin B with or without intravenous fluconazole followed by oral fluconazole or itraconazole (Group III)
Number of subjects: 22
Study: 9056056

Group type: EXPERIMENTAL
Intervention: Flumazenil (Anexate) 1 mg intravenously post bronchoscopy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo intravenously post bronchoscopy
Number of subjects: 22
Study: 8337995

Group type: COMPARATOR
Intervention: Group 1 (no ST segment depression)
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Group 2 (transient ST segment depression)
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Group 3 (persistent ST segment depression)
Number of subjects: 1444
Study: 3541415

Group type: EXPERIMENTAL
Intervention: 50 mg isosorbide-5-mononitrate (IS-5-MN) daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 X 20 mg nifedipine retard daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of both drugs for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isosorbide-5-mononitrate (IS-5-MN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Combination of both drugs
Number of subjects: 12
Study: 30922018

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) added to ISB with bupivacaine 0.3% and lidocaine 2%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketamine (50 mg) added to ISB with bupivacaine 0.3% and lidocaine 2%
Number of subjects: 60
Study: 26277090

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23943338

Group type: EXPERIMENTAL
Intervention: Off-label thrombolysis
Number of subjects: 500

Group type: COMPARATOR
Intervention: On-label thrombolysis (current European Alteplase license)
Number of subjects: 500
Study: 23791822

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (0·9 mg/kg) plus standard care (n=1515)
Number of subjects: 3035

Group type: COMPARATOR
Intervention: Standard care alone (control; n=1520)
Number of subjects: 3035
Study: 21111297

Group type: EXPERIMENTAL
Intervention: Group music activity (50-minute sessions, five times a week for 2 weeks)
Number of subjects: 67
Study: 18203711

Group type: EXPERIMENTAL
Intervention: Panipenem
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 116
Study: 16885388

Group type: EXPERIMENTAL
Intervention: ICSI children
Number of subjects: 304

Group type: COMPARATOR
Intervention: SC children
Number of subjects: 304
Study: 10825599

Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin A for 3 days just after each three doses of primary vaccination (Group I, n=24)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 150 mg oral vitamin E for only 1 day after the injections for primary immunization (Group II, n=21)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Vitamins A and E together in the same order (Group III, n=21)
Number of subjects: 89

Group type: COMPARATOR
Intervention: No vitamin after DPT vaccines (Group IV, n=23)
Number of subjects: 89
Study: 9239812

Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 1499480

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: High-glycemic index diet
Number of subjects: 6
Study: 3907323

Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 120 to 180 mg, 2 times a day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 to 50 mg, 2 times a day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination of diltiazem and hydrochlorothiazide
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 31026216

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 28851001

Group type: EXPERIMENTAL
Intervention: Early intervention group received a psychoeducational treatment program after a 6-week introduction period alongside psychodynamic treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late intervention group received psychoeducation 3 months after starting psychodynamic treatment.
Number of subjects: 0
Study: 26621183

Group type: EXPERIMENTAL
Intervention: CRT with prolonged QRS duration (182.5 ± 16.2 msec)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CRT with LV leads located in the posterolateral vein
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CRT with ΔQRS (QRS change)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CRT with biventricularly paced QRS
Number of subjects: 80
Study: 24766760

Group type: EXPERIMENTAL
Intervention: Transition to medication adoption
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Employment of at least one physician at baseline
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Greater proportion of Medicaid clients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Pharmaceutical detailing
Number of subjects: 190
Study: 22573119

Group type: EXPERIMENTAL
Intervention: Combination therapy (losartan/hydrochlorothiazide)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Maximal-dose ARB therapy
Number of subjects: 221
Study: 19882338

Group type: EXPERIMENTAL
Intervention: Alumina-on-alumina ceramic bearings
Number of subjects: 150

Group type: COMPARATOR
Intervention: Metal-on-highly cross-linked polyethylene bearings
Number of subjects: 150
Study: 18628657

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761) 300 mg/d
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 16637714

Group type: EXPERIMENTAL
Intervention: Cephalometric method 1
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cephalometric method 2
Number of subjects: 25
Study: 12663296

Group type: EXPERIMENTAL
Intervention: Borage oil supplement (containing 100 mg GLA)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sunflower oil supplement (placebo)
Number of subjects: 118
Study: 11379464

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phenytoin/Honey mixture
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 50
Study: 8945040

Group type: EXPERIMENTAL
Intervention: VRS pacing algorithm
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (50 ppm fixed rate pacing)
Number of subjects: 15
Study: 1323954

Group type: EXPERIMENTAL
Intervention: Temafloxacin at 600 mg twice daily
Number of subjects: 246

Group type: COMPARATOR
Intervention: Amoxicillin at 500 mg three times daily
Number of subjects: 246
Study: 6394068

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mgs bid administered during chemotherapy and continued in 43 patients for up to five years after termination of chemotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: No tamoxifen
Number of subjects: 124
Study: 31685792

Group type: EXPERIMENTAL
Intervention: Dapagliflozin and metformin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Glimepiride and metformin
Number of subjects: 36
Study: 29070564

Group type: EXPERIMENTAL
Intervention: Capsulated mustard
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Uncapsulated mustard
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 25392325

Group type: EXPERIMENTAL
Intervention: GNbAC1 (2 or 6 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23279823

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) during a working memory task
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy controls (N=16)
Number of subjects: 8
Study: 21314870

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-30 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine (10-20 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 60
Study: 18485414

Group type: EXPERIMENTAL
Intervention: Intraprostatic lidocaine injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Periprostatic infiltration alone (0.9% NaCl)
Number of subjects: 200
Study: 16972105

Group type: EXPERIMENTAL
Intervention: 384 mg naltrexone base
Number of subjects: 5

Group type: COMPARATOR
Intervention: Heroin doses (0, 6.25, 12.5, and 25 mg, i.v.)
Number of subjects: 5
Study: 14521737

Group type: EXPERIMENTAL
Intervention: Reduced glutathione (30 mg/kg) in priming fluid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no reduced glutathione)
Number of subjects: 20